<DOC>
	<DOCNO>NCT02843386</DOCNO>
	<brief_summary>After local treatment primary tumor ( protonbeam-therapy , enucleation , external radiotherapy ) patient high risk metastasis randomize : - Adjuvant chemotherapy Fotemustin . - Observation Both group follow 3 year Metastasis- Free Survival , safety tolerance Fotemustin , quality life , Overall Survival .</brief_summary>
	<brief_title>Randomized Phase III Study Comparing Adjuvant Chemotherapy With Fotemustin Intensive Surveillance Patients With High Risk Uveal Melanoma</brief_title>
	<detailed_description>High risk uveal melanoma define : - Clinical criterion : Largest Tumor Diameter ≥ 15 mm extra scleral extension and/or retinal detachment Largest Tumor Diameter ≥ 18 mm AND/ OR - Genomic high risk signature ( aCGH +/-LOH ) : Monosomy 3 partial deletion 3p associate 8 gain . Treatment schedule : - Induction : Fotemustin 100 mg/m² , D1-D8-D15 , 1 hour IV infusion , 1 cycle - Maintenance : restart D50 , Fotemustine : 100 mg/m² , 1 hour IV infusion , D1 D21 , 5 cycle . Both group follow 3 year Metastasis- Free Survival , safety tolerance Fotemustin , quality life , Overall Survival . Note : Based second interim analysis show futility , chance observe significant statistical difference end study , Independent Data Monitoring Committee recommend stop randomization amend protocol propose interventional surveillance high-risk patient per protocol ( April 2016 ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>1 . High risk uveal melanoma , define : Clinical criterion : Largest Tumor Diameter ≥ 15 mm extrascleral extension and/or retinal detachment Largest Tumor Diameter ≥ 18 mm AND/OR Genomic high risk signature ( cCGH +/ LOH ) : Monosomy 3 partial deletion 3p 8 gain , enucleation , transscleral transvitreal sample 2 . Age ≥ 18 year ECOG Performance Status ≤ 2 3 . No prior chemotherapy history invasive cancer &lt; 5years 4 . No metastasis 5 . Local treatment primary tumour ( surgery and/or radiotherapy ) achieve ≤ 30 day randomization , chemotherapy begin within 15 day . 6 Contraception woman childbearing potential 7 Written inform consent 8 Patients French Social Security compliance French law relate biomedical research . Non 1 . Largest Tumor Diameter &lt; 15 mm Largest Tumor Diameter 1518 mm without extrascleral extension and/or retinal detachment , absence genomic alteration define per protocol absence Fine Needle Aspiration biopsy genomic risk assessment . 2 . Contraindication Fotemustine administration 3 . Hematological function : Hb &lt; 10g/dL , absolute neutrophil count &lt; 2,000/mm3 , platelet &lt; 100,000/mm3 4 . Biochemistry result : Total bilirubin AST/ALT &gt; 1,5 UNL ( Upper Normal Limit ) 5 . Creatinine &gt; 1,5 UNL ( Upper Normal Limit ) 6 . Pregnant and/or breastfeed woman . 8 Previous history cancer except situ cervical carcinoma cutaneous basal carcinoma . 7 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , viral hepatitis cirrhosis , psychiatric illness/social situation would interfere protocol limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>High risk metastasis</keyword>
	<keyword>Genomic high risk signature</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
</DOC>